You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: Systematic review and meta‐analysis
|
|---|---|
| Published in |
Hepatology, May 2017
|
| DOI | 10.1002/hep.29085 |
| Pubmed ID | |
| Authors |
Parambir S. Dulai, Siddharth Singh, Janki Patel, Meera Soni, Larry J. Prokop, Zobair Younossi, Giada Sebastiani, Mattias Ekstedt, Hannes Hagstrom, Patrik Nasr, Per Stal, Vincent Wai‐Sun Wong, Stergios Kechagias, Rolf Hultcrantz, Rohit Loomba |
| Abstract |
Liver fibrosis is the most important predictor of mortality in nonalcoholic fatty liver disease (NAFLD). Quantitative risk of mortality by fibrosis stage has not been systematically evaluated. We aimed to quantify the fibrosis stage-specific risk of all-cause and liver-related mortality in NAFLD. Through a systematic review and meta-analysis, we identified 5 adult NAFLD cohort studies reporting fibrosis stage specific mortality (0-4). Using fibrosis stage 0 as a reference population, fibrosis stage-specific mortality rate ratios (MRR) with 95% confidence intervals (CI), for all-cause and liver-related mortality, were estimated. The study is reported according to the PRISMA statement. 1,495 NAFLD patients with 17,452 patient years of follow-up were included. Compared to NAFLD patients with no fibrosis (stage 0), NAFLD patients with fibrosis were at an increased risk for all-cause mortality and this risk increased with increase in the stage of fibrosis: stage 1, MRR, 1.58 (95% CI 1.19-2.11); stage 2, MRR, 2.52 (95% CI 1.85-3.42); stage 3, MRR, 3.48 (95% CI 2.51-4.83), and stage 4, MRR, 6.40 (95% CI 4.11-9.95). The results were more pronounced as the risk of liver-related mortality increased exponentially with increase in the stage of fibrosis: stage 1, MRR, 1.41 (95% CI 0.17-11.95); stage 2, MRR, 9.57 (95% CI 1.67-54.93); stage 3, MRR, 16.69 (95% CI 2.92-95.36); and stage 4, MRR, 42.30 (95% CI 3.51-510.34). Inability to adjust for co-morbid conditions or demographics known to impact fibrosis progression in NAFLD, and the inclusion of patients with simple steatosis and NASH without fibrosis in the reference comparison group. The risk of liver-related mortality increases exponentially with increase in fibrosis stage. These data have important implications in assessing utility of each stage and benefits of regression of fibrosis from one stage to another. This article is protected by copyright. All rights reserved. |
X Demographics
The data shown below were collected from the profiles of 25 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 9 | 36% |
| Japan | 2 | 8% |
| Brazil | 2 | 8% |
| United Kingdom | 1 | 4% |
| Sri Lanka | 1 | 4% |
| Spain | 1 | 4% |
| Switzerland | 1 | 4% |
| Austria | 1 | 4% |
| Unknown | 7 | 28% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 14 | 56% |
| Scientists | 7 | 28% |
| Practitioners (doctors, other healthcare professionals) | 3 | 12% |
| Science communicators (journalists, bloggers, editors) | 1 | 4% |
Mendeley readers
The data shown below were compiled from readership statistics for 513 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 513 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 57 | 11% |
| Student > Ph. D. Student | 56 | 11% |
| Student > Master | 55 | 11% |
| Other | 49 | 10% |
| Student > Bachelor | 34 | 7% |
| Other | 100 | 19% |
| Unknown | 162 | 32% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 178 | 35% |
| Biochemistry, Genetics and Molecular Biology | 37 | 7% |
| Pharmacology, Toxicology and Pharmaceutical Science | 20 | 4% |
| Agricultural and Biological Sciences | 19 | 4% |
| Nursing and Health Professions | 15 | 3% |
| Other | 58 | 11% |
| Unknown | 186 | 36% |
Attention Score in Context
This research output has an Altmetric Attention Score of 409. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 02 January 2024.
All research outputs
#73,375
of 26,017,215 outputs
Outputs from Hepatology
#32
of 9,183 outputs
Outputs of similar age
#1,712
of 327,148 outputs
Outputs of similar age from Hepatology
#3
of 104 outputs
Altmetric has tracked 26,017,215 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 99th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 9,183 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 10.5. This one has done particularly well, scoring higher than 99% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 327,148 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 99% of its contemporaries.
We're also able to compare this research output to 104 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 97% of its contemporaries.